Vijaya Diagnostic Centre Limited (NSE:VIJAYA)

India · Delayed Price · Currency is INR

1,504.40

+6.00 (0.40%)

Aug 21, 2026, 3:30 PM IST

44.82% (1Y)

Market Cap	154.80B +45.1%
Revenue (ttm)	8.57B +20.2%
Net Income	1.87B +24.9%
EPS	18.19 +24.4%
Shares Out	102.90M
PE Ratio	82.71
Forward PE	64.76
Dividend	2.00 (0.13%)
Ex-Dividend Date	Sep 16, 2026

Volume	97,322
Open	1,505.00
Previous Close	1,498.40
Day's Range	1,470.60 - 1,510.00
52-Week Range	848.00 - 1,573.00
Beta	0.34
Analysts	Strong Buy
Price Target	1,530.30 (+1.72%)
Earnings Date	Aug 6, 2026

About Vijaya Diagnostic Centre

Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, molecular diagnostics, CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, gastroenterology, nuclear medicine and PET/CT, and MRI-3T services. It also provides health checkups and home sample collection services. Vijaya Diagnostic Centre Limited was founded in 1981 and is based in Hyder... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 1981

Employees 2,218

Stock Exchange National Stock Exchange of India

Ticker Symbol VIJAYA

Full Company Profile

Financial Performance

In fiscal year 2026, Vijaya Diagnostic Centre's revenue was 8.14 billion, an increase of 19.49% compared to the previous year's 6.81 billion. Earnings were 1.73 billion, an increase of 20.90%.

Financial Statements

Analyst Summary

According to 9 analysts, the average rating for VIJAYA stock is "Strong Buy." The 12-month stock price target is ₹1,530, which is an increase of 1.72% from the latest price.

Price Target

₹1,530

(1.72% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Vijaya Diagnostic Centre Transcript: Q1 26/27

Q1 FY27 saw 22.8% revenue growth and 34% EBITDA growth, driven by network expansion and strong B2C performance. Expansion plans include nine new hubs and 10-12 spokes, with CapEx of INR 190-195 crore and EBITDA margin guidance above 40%.

15 days ago - Transcripts

Vijaya Diagnostic Centre Quarterly report: Q1 2027

Vijaya Diagnostic Centre has published its Q1 2027 quarterly earnings report on August 7, 2026.

15 days ago - Filings

Vijaya Diagnostic Centre Slides: Q1 2027

Vijaya Diagnostic Centre has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 7, 2026.

15 days ago - Filings

Vijaya Diagnostic Centre Transcript: Q4 25/26

Q4 FY 2026 saw 26.6% YoY revenue growth and 43.5% EBITDA margin, driven by strong volume and network expansion. FY 2026 revenue reached INR 814 crore, with robust growth across core and new geographies, and continued investment in technology and talent.

3 months ago - Transcripts

Vijaya Diagnostic Centre Quarterly report: Q4 2026

Vijaya Diagnostic Centre has published its Q4 2026 quarterly earnings report on May 8, 2026.

3 months ago - Filings

Vijaya Diagnostic Centre Slides: Q4 2026

Vijaya Diagnostic Centre has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 8, 2026.

3 months ago - Filings

Vijaya Diagnostic Centre Transcript: Q3 25/26

Q3 FY26 saw record revenue of INR 205 crore, up 21.4% year-over-year, with strong growth in both radiology and pathology. EBITDA margin improved to 41.9%, and the wellness segment reached 15% of revenue. Expansion continues with a focus on stabilizing new hubs and investing in technology.

6 months ago - Transcripts